Strategic MAnagement to Optimize Response To Cardiac Resynchronization Therapy - SMART CRT

Boston Scientific Corporation Rhythm Management0 个研究点目标入组 726 人开始时间: 2018年6月28日最近更新: 2023年10月17日

试验速览

暂无简介。

•Subjects with documented permanent complete AV block Subjects with permanent or chronic atrial fibrillation (AF) or in AF at the time of enrollment Subjects who have previously received cardiac resynchronization therapy with pacing in the left ventricle Subjects on the active heart transplant list or who has or is to receive ventricular assist device (VAD) Life expectancy shorter than 12 months due to any medical condition (e.g., cancer, uremia, liver failure, etc) Subject with a known or suspected sensitivity to dexamethasone acetate (DXA) Subject is enrolled in any other concurrent clinical study, with the exception of local mandatory governmental registries and observational studies/registries, without the written approval from Boston Scientific Women of childbearing potential who are or plan to become pregnant during the course of the trial Subjects currently requiring dialysis

发起方

Boston Scientific Corporation Rhythm Management